Numerai GP LLC Acquires Shares of 8,640 Danaher Co. (NYSE:DHR)

Numerai GP LLC bought a new position in shares of Danaher Co. (NYSE:DHR) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 8,640 shares of the conglomerate’s stock, valued at approximately $1,983,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter worth approximately $27,000. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the 4th quarter worth approximately $31,000. Golden State Wealth Management LLC purchased a new position in shares of Danaher in the 4th quarter worth approximately $31,000. Hurley Capital LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $34,000. Finally, Pineridge Advisors LLC increased its position in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

Shares of NYSE DHR opened at $196.60 on Wednesday. The stock has a fifty day moving average of $197.83 and a 200-day moving average of $218.54. The stock has a market cap of $140.70 billion, a PE ratio of 37.23, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Equities research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher’s payout ratio is currently 24.85%.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Barclays boosted their price objective on Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 22nd. Guggenheim reissued a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. The Goldman Sachs Group reduced their price target on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Finally, Wells Fargo & Company dropped their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $264.40.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.